Results 71 to 80 of about 53,113 (297)

Fatal acquired coagulation factor V deficiency after hepatectomy for advanced hepatocellular carcinoma as a possible immune checkpoint inhibitor-related adverse event: a case report

Surgical Case Reports, 2023
Background Atezolizumab plus bevacizumab therapy was recently introduced as the first line for unresectable advanced hepatocellular carcinoma (HCC), but immune-related adverse events (IrAEs) due to atezolizumab are a great concern.
Shintaro Arakaki, Shinichiro Ono, Futoshi Kawamata, Shinichiro Ishino, Yasunori Uesato, Tomo Nakajima, Yukiko Nishi, Satoko Morishima, Shingo Arakaki, Tatsuji Maeshiro, Masayoshi Souri, Akitada Ichinose, Hiroaki Masuzaki, Mitsuhisa Takatsuki   +13 more
doaj   +1 more source

Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Advanced Non-small Cell Lung Cancer: A Network Meta-Analysis of Randomized Clinical Trials

Frontiers in Pharmacology, 2021
Objective: This network meta-analysis will provide a complete toxicity profile, toxicity profile, and safety ranking of immune checkpoint inhibitors (ICIs) for treatment of advanced non-small cell lung cancer (NSCLC).Methods: We found 12 phase II or III ...
Weidong Zhang, Jingjing Gu, Chunming Bian, Guanhong Huang   +3 more
doaj   +1 more source

Advanced Human Immune Cell‐Organoid Co‐Cultures for Functional Testing of Cancer Nanovaccines

Advanced Science, EarlyView.
Pancreatic ductal adenocarcinoma remains difficult to treat. We establish an organoid–immune co‐culture using patient‐derived organoids and matched T‐cells to assess cancer vaccines. A mesothelin‐targeted nanovaccine activates antigen‐specific T‐cells, increases IFN‐γ, and targets MSLN+ organoids.
Nathalia Ferreira, David Agorku, Andre Rosa, Julia Roosz, Lena Christ, Nicole Anderle, Ajinkya Kulkarni, Abir Hussein, Sana S. Sayedipour, Omar F. Luna, Tobias Legler, Philipp Ströbel, Fernando Albericio, Luis Cruz, Phillipp Beckhove, Peter Loskill, Frauke Alves, M. Andrea Markus, Fernanda Ramos‐Gomes   +18 more
wiley   +1 more source

Triple Negative Breast Cancer - Review of Current and Emerging Therapeutic Strategies [PDF]

, 2016
Triple negative breast cancer (TNBC) is associated with a poor prognosis compared to other types of breast cancer. The classification of 'triple negative' is not one homogenous tumor type, but rather is made up of multiple molecularly and biologically ...
Ballinger, Tarah, Kremer, Jill, Miller, Kathy   +2 more
core   +1 more source

Current Status of Multidisciplinary Treatment Strategies for Hepatocellular Carcinoma in the Era of Advanced Systemic Therapies

Annals of Gastroenterological Surgery, EarlyView.
ABSTRACT The therapeutic landscape of hepatocellular carcinoma (HCC) has been transformed by recent advancements in systemic therapies, particularly with the introduction of immune checkpoint inhibitors, expanding treatment options beyond conventional locoregional approaches.
Keiichi Akahoshi, Shun Kaneko, Shinji Tanaka, Minoru Tanabe, Daisuke Ban   +4 more
wiley   +1 more source

Tumor immune microenvironment and genomic evolution in a patient with metastatic triple negative breast cancer and a complete response to atezolizumab

Journal for ImmunoTherapy of Cancer, 2019
Background Metastatic TNBC (mTNBC) has a poor prognosis and few treatment options. The anti-PD-L1 antibody atezolizumab demonstrated clinical activity in mTNBC patients with PD-L1-positive tumor-infiltrating immune cells.
Luciana Molinero, Yijin Li, Ching-Wei Chang, Sophia Maund, Maureen Berg, Jeanne Harrison, Marcella Fassò, Carol O’Hear, Priti Hegde, Leisha A. Emens   +9 more
doaj   +1 more source

Association of HAMP Expression and CD8+ T‐Cell Infiltration With Atezolizumab–Bevacizumab Response in Hepatocellular Carcinoma

Annals of Gastroenterological Surgery, EarlyView.
In hepatocellular carcinoma treated with atezolizumab–bevacizumab, responders showed RNA‐seq enrichment of immune and chemokine pathways with higher HAMP expression. In resected specimens, immunohistochemistry confirmed increased intratumoral CD8+ T‐cell density and hepcidin (HAMP), supporting HAMP plus CD8 as components of a composite predictor of ...
Shun Nakamura, Yuki Murakami, Yusuke Oshima, Takashi Masuda, Wataru Miyoshino, Hiroomi Takayama, Yoko Kawano, Teijiro Hirashita, Yuichi Endo, Masafumi Inomata   +9 more
wiley   +1 more source

Maximum Somatic Allele Frequency in Combination With Blood-Based Tumor Mutational Burden to Predict the Efficacy of Atezolizumab in Advanced Non-small Cell Lung Cancer: A Pooled Analysis of the Randomized POPLAR and OAK Studies

Frontiers in Oncology, 2019
Background: Blood-based tumor mutational burden (bTMB) was recently found to be suboptimal in predicting overall survival (OS) benefits of atezolizumab over docetaxel among patients with advanced non-small cell lung cancer (NSCLC).
Yu-tong Chen, Sharvesh Raj Seeruttun, Xiang-yuan Wu, Zi-xian Wang   +3 more
doaj   +1 more source

Immune checkpoint inhibitors for advanced non-small cell lung cancer: emerging sequencing for new treatment targets [PDF]

, 2017
Lung cancer is the leading cause of cancer-related deaths in the world. Immune checkpoint inhibitors (ICI) stimulate cytotoxic lymphocyte activity against tumour cells.
Abdel-Rahman, Aguiar, Aguiar, Alfonso, Altekruse, Antonia, Antonia, Barlesi, Beatty, Bonnesen, Borghaei, Borghaei, Brahmer, Brahmer, Brahmer, Bunn, Butts, Carney, Chen, Creelan, de, Dudley, Dudley, Fehrenbacher, Feinstein, Ferlay, Garon, Gettinger, Gulley, Hanahan, Hashim, Hellmann, Hellmann, Herbst, Herbst, Hirsch, Hodi, Horn, Iyengar, Kotsakis, Langer, Lawrence, Masters, Matter-Walstra, Maude, Mok, Nemunaitis, Nemunaitis, Nicholaou, Passiglia, Patel, Quoix, Reck, Rittmeyer, Rizvi, Rizvi, Robbins, Rosell, Rosenberg, Sandler, Sandler, Scagliotti, Schiller, Sequist, Siegel, Sienel, Socinski, Solomon, Wolchok, Wozniak   +69 more
core   +3 more sources

Surgical Outcomes and Recurrence Management in Borderline Resectable Hepatocellular Carcinoma: Implications for Multidisciplinary Strategies

Annals of Gastroenterological Surgery, EarlyView.
Multivariate analysis identified that up‐to‐7 out (p < 0.001), lymph node metastasis (p < 0.001), and non‐anatomical resection (p = 0.02) were independent predictors of cancer recurrence, while older age (p = 0.01), Child‐Pugh B (p < 0.001), up‐to‐7 out (p = 0.01), macrovascular invasion (p = 0.01), and lymph node metastasis (p < 0.001) were ...
Koichiro Haruki, Kenei Furukawa, Munetoshi Akaoka, Yuto Yamahata, Shinji Onda, Yoshihiro Shirai, Masashi Tsunematsu, Tomohiko Taniai, Michinori Matsumoto, Toru Ikegami   +9 more
wiley   +1 more source